Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2716019 | 0.84 | ALDH1A1 (0.63) | ALDH1A1POLBSMN1; SMN2LMNAPLA2G7 | |
| SCHEMBL8282723 | 0.80 | SMN1; SMN2 (0.56) | ALDH1A1POLBSMN1; SMN2LMNAMAPT | |
| SCHEMBL2713998 | 0.80 | PLA2G7 (0.32) | PLA2G7 | |
| SCHEMBL15424627 | 0.77 | POLB (0.59) | ALDH1A1POLBSMN1; SMN2LMNAPLA2G7 | |
| SCHEMBL2712390 | 0.77 | ALDH1A1 (0.49) | ALDH1A1POLBSMN1; SMN2LMNAPLA2G7 | |
| SCHEMBL8282749 | 0.75 | SMN1; SMN2 (0.59) | ALDH1A1POLBSMN1; SMN2LMNAPLA2G7 | |
| SCHEMBL17479914 | 0.75 | PLA2G7 (0.42) | PLA2G7 | |
| SCHEMBL6113611 | 0.74 | CA2 (0.33) | — | |
| SCHEMBL2879955 | 0.72 | CA2 (0.52) | — | |
| SCHEMBL3245578 | 0.71 | POLB (0.55) | ALDH1A1POLBSMN1; SMN2LMNAPLA2G7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9248117-B2 | Substituted N,N-dihaloamines as antimicrobials | NOVABAY PHARMACEUTICALS, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| EP-2629607-A2 | ANTIMICROBIAL POLYETHER AND POLYOL COMPOUNDS | NovaBay Pharmaceuticals, Inc. (US) | 2013-08-28 | — | — | EP | disclosed |
| US-20120129793-A1 | Antimicrobial Polyether and Polyol Compounds | NOVABAY PHARMACEUTICALS, INC. | 2012-05-24 | — | — | US | disclosed |
| WO-2012054521-A2 | ANTIMICROBIAL POLYETHER AND POLYOL COMPOUNDS | NOVABAY PHARMACEUTICLAS, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129793-A1 | Antimicrobial Polyether and Polyol Compounds | POLR1C, DPM1, PRF1 | ALDH1A1 1198/4885POLB 130/4885SMN1; SMN2 2872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.